Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Results from the phase I ICONIC trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 465
Rating:

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Dr Yap speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about data from the ICONIC trial of ICOS agonist antibody JTX-2011, a first-in-class drug.

He outlines the mechanistic and pharmacodynamic rationale behind developing an ICOS agonist, and dosages in the ICONIC trial of JTX-2011 with or without nivolumab in advanced cancers.

Dr Yap highlights responses in gastric, breast and lung cancers, and introduces ongoing trials for JTX-2011 in combination with CTLA-4 checkpoint therapy.

Related videos

18.10.18

no rating
For HSCT in Ph-positive ALL

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation